Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000776
Status:
COMPLETED
Last Update Posted:
2021-10-28
First Post:
1999-11-02
Brief Title:
Dexamethasone in Cryptococcal Meningitis
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Dexamethasone in Cryptococcal Meningitis
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension
In AIDS patients with cryptococcal meningitis a correlation has been found between early death and elevated intracranial pressure Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis it may be of benefit in AIDS patients with cryptococcal meningitis
In AIDS patients with cryptococcal meningitis a correlation has been found between early death and elevated intracranial pressure Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis it may be of benefit in AIDS patients with cryptococcal meningitis
Detailed Description:
In AIDS patients with cryptococcal meningitis a correlation has been found between early death and elevated intracranial pressure Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis it may be of benefit in AIDS patients with cryptococcal meningitis
Patients are randomized to receive dexamethasone or placebo every 6 hours for 72 hours days 1 through 3 Additionally standard antifungal therapy with amphotericin B and flucytosine is given for 2 weeks followed by fluconazole for 8 weeks Lumbar punctures will be performed daily on days 1 through 3 on days 7 and 14 and at week 10
Patients are randomized to receive dexamethasone or placebo every 6 hours for 72 hours days 1 through 3 Additionally standard antifungal therapy with amphotericin B and flucytosine is given for 2 weeks followed by fluconazole for 8 weeks Lumbar punctures will be performed daily on days 1 through 3 on days 7 and 14 and at week 10
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 11178 | REGISTRY | DAIDS ES Registry Number | None |